SynAct Pharma AB stock analysis
Want to see SE:SYNACT full AI Analyst Report?
SynAct Pharma AB (SYNACT) Stock Price & Analysis
SYNACT Stock Chart & Stats
- Day’s Range
- SEK 13.50 - SEK 14.74
- 52-Week Range
- SEK 7.05 - SEK 24.50
- Previous Close
- SEK 13.22
- Volume
- N/A
- Average Volume (3M)
- 108.95K
- Market Cap
- SEK 743.15M
- Enterprise Value
- SEK 986.91M
- Total Cash (Recent Filing)
- SEK 42.36M
- Total Debt (Recent Filing)
- SEK 45.53M
- Price to Earnings (P/E)
- ―
- Beta
- -0.15
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
The balance sheet’s meaningful equity base and very low debt relative to equity provide some financial flexibility while SynAct advances development. This is a durable offset to its weak earnings profile, although ongoing losses could still erode that cushion over time.
Differentiated Inflammation Approach
SynAct is pursuing a differentiated inflammation strategy intended to resolve inflammation without broadly suppressing the immune system. If clinical data support that approach, the mechanism could provide a durable basis for development and partnering interest across autoimmune indications.
Oral Lead Candidate
Resomelagon is an orally administered melanocortin receptor agonist being evaluated in rheumatoid arthritis and other inflammatory or autoimmune conditions. A single development program spanning multiple indications gives SynAct a coherent platform for creating value from clinical milestones.
Bears Say
No Commercial Revenue
The absence of reported revenue means SynAct has not yet established a commercial engine to fund research and development internally. Its financial outlook therefore remains dependent on clinical progress, external financing, or future partnering and commercialization.
Persistent Cash Burn
Persistent negative operating and free cash flow requires SynAct to keep funding development despite limited internal cash generation. Continued burn can reduce financial flexibility and increase reliance on future capital raises or other financing sources over the next several quarters.
Sustained Losses And Dilution Risk
Large recurring losses weaken returns on the existing equity base and can increase the need for additional financing. If cash requirements remain elevated, future equity issuance could dilute current shareholders and constrain the company’s ability to fund its pipeline independently.
SynAct Pharma AB News
SynAct Announces U.S. Patent Allowance for Resomelagon Tablet
SynAct Pharma AB ( ($SE:SYNACT) ) just unveiled an announcement. SynAct Pharma is a clinical-stage biotechnology company focused on inflammation, developing oral small-molecule and injectable peptide melanocortin agonists. Its lead
SynAct Pharma Publishes Interim Report for January–September 2026
SynAct Pharma AB ( ($SE:SYNACT) ) has shared an announcement. SynAct Pharma released its interim report covering January through September 2026, outlining third-quarter developments, research and development activities, and financial
SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals
SynAct Pharma AB ( ($SE:SYNACT) ) just unveiled an update. SynAct Pharma has released further analysis from its Phase 2b ADVANCE study of resomelagon in treatment-naïve rheumatoid arthritis patients, reinforcing
SYNACT FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
What is SynAct Pharma AB’s market cap?
When is SynAct Pharma AB’s upcoming earnings report date?
How were SynAct Pharma AB’s earnings last quarter?
Is SynAct Pharma AB overvalued?
Does SynAct Pharma AB pay dividends?
What is SynAct Pharma AB’s EPS estimate?
How many shares outstanding does SynAct Pharma AB have?
What happened to SynAct Pharma AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of SynAct Pharma AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeppe Ovli Ovlesen
- Employees
- 8
- Website
- www.synactpharma.com
- Address
- Scheelevägen 2, Lund, SN, 223 63, SE
SynAct Pharma AB (SYNACT) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |









